Physician profile
Christina S Wise
NPI 1730342635
$2,809.71
in general payments reported to CMS, 2019-2025
14 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.08 · 2020: $85.74 · 2021: $360 · 2022: $431 · 2023: $422 · 2024: $990 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.93 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,181.63 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $431.13 | 2023-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $388.10 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $187.08 | 2019-2023 | Rexulti |
| Alkermes, INC. | $147.11 | 2019-2023 | Vivitrol |
| Axsome Therapeutics, INC. | $124.31 | 2024-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $122.44 | 2022-2025 | Fanapt, Hetlioz |
| Braeburn INC. | $60.16 | 2024-2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $55.28 | 2024-2025 | Spravato |
| Neurocrine Biosciences, INC. | $38.21 | 2024 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $32.42 | 2022 | |
| Allergan, INC. | $15.63 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.29 | 2022 | |
| Mdd US Operations, LLC | $12.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.